Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02284


Purpose:

Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.


Study summary:

Minimum age: 18 years old (at time of inclusion in the CA184-367- but 16 for the EAP)


Criteria:

Inclusion Criteria: - Patients have been enrolled in the EAPs - Patients still alive must provide informed consent if required by local regulations - Deceased patients are eligible per local regulations, their legal representatives must provide informed consent if required by local regulations Exclusion Criteria: - There are no specific exclusion criteria in this observational study other than the exclusion criteria of the EAP


NCT ID:

NCT02492815


Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02284
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.